UK adopts EC variations regulation
Guidance has been published in the UK regarding a new European variations regulation that comes into effect on 1 January 2010.
Guidance has been published in the UK regarding a new European variations regulation that comes into effect on 1 January 2010. After consultation, UK health ministers have agreed that the new rules will be adopted for all variations to marketing authorizations, including those held only in the UK. Additionally, an amending fees regulation will be implemented in the UK to establish fees for the new types of work specified in the Commission regulation. The information has been published on the UK's Medicines and Healthcare products Regulatory Agency (MHRA) website.
, which will replace Regulations 1084/2003/EC and 1085/2003/EC, concerns variations to the terms of marketing authorizations that have been granted by the Commission in Centralized Procedures and by the National Licensing Authorities in Mutual Recognition, Decentralized or other 'harmonizing' European Procedures.
According to the MHRA, the Commission also intends to extend the scope of the regulation to include variations to 'purely National' marketing authorizations. This will require further legislative changes and will probably not be implemented until 2011. UK health ministers, however, have agreed that the rules within the new regulation will be adopted for all variations to the terms of marketing authorizations, including those granted in 'purely National' procedures.
The UK agency has also introduced, as of 1 January 2010, new fee categories to cover grouped and bulk-group applications for multiple changes submitted as part of the same variation application and applications where the UK is the 'Reference Authority' in a European worksharing procedure.
Further details can be found in the MHRA's National MA Variations Guidance.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
